Ipsen makes investment in Syntaxin as part of Syntaxin's £18 million financing

Client

Ipsen Limited

Date

November 17, 2010

On 11 November 2010, biotech firm Syntaxin announced it had successfully raised £18 million in a Series C funding round with new and existing investors.

New investors Lundbeckfond Ventures, Ipsen, and Seventure have joined existing investors Abingworth, SROne, LSP, Johnson & Johnson Develpment, and Quest.

Fasken Martineau advised Ipsen in this transaction with a team comprised of Allistair Booth, Charles Waddell, Robert Paydon, Antonina Cuffaro, Fiona Wheatley, Zehra Kasapoglu and Victoria Mundy.